| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.COPH.2005.11.003 |
| P698 | PubMed publication ID | 16376147 |
| P50 | author | Graeme J Sills | Q60351421 |
| P433 | issue | 1 | |
| P921 | main subject | gabapentin | Q410352 |
| pharmacology | Q128406 | ||
| P304 | page(s) | 108-113 | |
| P577 | publication date | 2005-12-22 | |
| P1433 | published in | Current Opinion in Pharmacology | Q3007702 |
| P1476 | title | The mechanisms of action of gabapentin and pregabalin | |
| P478 | volume | 6 |
| Q41943842 | A Case Report of Syndrome of Inappropriate Antidiuretic Hormone Induced by Pregabalin |
| Q37785529 | A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin |
| Q92236568 | A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy |
| Q35982249 | A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults |
| Q43154709 | A rare case of bilateral lower extremity edema due to low dose gabapentin therapy in a young male patient |
| Q47816185 | A review of Neuropathic Pain: From Guidelines to Clinical Practice |
| Q38266188 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough |
| Q30179405 | A β-amyloid oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes |
| Q38412820 | Activation of the γ-Aminobutyric Acid Type B (GABA(B)) Receptor by Agonists and Positive Allosteric Modulators. |
| Q47182010 | Advances in Pharmacotherapy Development: Human Clinical Studies |
| Q38863864 | Alcohol Dependence Disrupts Amygdalar L-Type Voltage-Gated Calcium Channel Mechanisms. |
| Q91600342 | An Overview of Pharmacotherapy Options for Alcohol Use Disorder |
| Q44343213 | An exploratory study Evaluating the impact of opioid and non-opioid pain medications on serum/plasma free testosterone and free estradiol concentrations |
| Q38002650 | An overview of the physiology of pain for the veterinarian |
| Q56113559 | Analgesics and Antipyretics |
| Q53112986 | Anticonvulsant Activity of Enantiomeric N-trans-Cinnamoyl Derivatives of 2-Aminopropan-1-ols and 2-Aminobutan-1-ols. |
| Q64265575 | Anticonvulsants for behavioral and psychological symptoms in dementia: protocol for a systematic review |
| Q34472695 | Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders |
| Q37029357 | Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy |
| Q37878206 | Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update |
| Q55355846 | Brain GABA and Glutamate Concentrations Following Chronic Gabapentin Administration: A Convenience Sample Studied During Early Abstinence From Alcohol. |
| Q34100677 | Bupropion for the treatment of neuropathic pain |
| Q36805266 | Cellular and behavioral interactions of gabapentin with alcohol dependence |
| Q38178789 | Chronic cough as a neuropathic disorder. |
| Q88651735 | Chronic low back pain: a mini-review on pharmacological management and pathophysiological insights from clinical and pre-clinical data |
| Q37418980 | Clinical use of pregabalin in the management of central neuropathic pain |
| Q42660985 | Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain |
| Q44456466 | Comparison of gabapentin versus topiramate on clinically affected dogs with Chiari-like malformation and syringomyelia. |
| Q37392010 | Corneal pain without stain: is it real? |
| Q36372867 | Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse |
| Q28297699 | De Novo mutations in GNAO1, encoding a Gαo subunit of heterotrimeric G proteins, cause epileptic encephalopathy |
| Q39966055 | De novo GABRA1 mutations in Ohtahara and West syndromes |
| Q39302418 | Decrease in tobacco consumption after treatment with topiramate and aripiprazole: a case report. |
| Q42922796 | Design, synthesis and hydrolytic behavior of mutual prodrugs of NSAIDs with gabapentin using glycol spacers |
| Q38829642 | Desmoid Tumors: A Review of the Literature and Pharmacologic Management. |
| Q37383571 | Development of pharmacotherapies for drug addiction: a Rosetta stone approach |
| Q46761500 | Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats |
| Q40701817 | Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. |
| Q51736792 | Does low-dose gapapentin reduce opioid use postoperatively?: A randomized controlled trial in women undergoing reconstructive pelvic surgery. |
| Q52149350 | Early metabolic responses to lithium/pilocarpine-induced status epilepticus in rat brain. |
| Q46252236 | Effects of gabapentin and pregabalin on K+-evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes |
| Q37203346 | Efficacy and tolerability of pregabalin in partial epilepsy. |
| Q90158223 | Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial |
| Q54219723 | Efficacy of sertraline and gabapentin in the treatment of urethral pain syndrome: retrospective results of a single institutional cohort. |
| Q51700780 | Enantioselective sp(3) C-H alkylation of γ-butyrolactam by a chiral Ir(I) catalyst for the synthesis of 4-substituted γ-amino acids. |
| Q64079591 | Esophagogastric Junction Outflow Obstruction Caused by Gabapentin |
| Q35061649 | Ethanol, not detectably metabolized in brain, significantly reduces brain metabolism, probably via action at specific GABA(A) receptors and has measureable metabolic effects at very low concentrations |
| Q58588505 | Evaluation of the effects of pregabalin on chondrocyte proliferation and , α, and gene expression |
| Q35738163 | Evaluation of the neurological safety of epidurally-administered pregabalin in rats |
| Q37460503 | Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment |
| Q38968433 | Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? |
| Q81487952 | Gabapentin |
| Q64993401 | Gabapentin Can Suppress Cell Proliferation Independent of the Cytosolic Branched-Chain Amino Acid Transferase 1 (BCAT1). |
| Q58591817 | Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial assessing Efficacy and Safety |
| Q51097744 | Gabapentin Inhibits Protein Kinase C Epsilon Translocation in Cultured Sensory Neurons with Additive Effects When Coapplied with Paracetamol (Acetaminophen). |
| Q90321112 | Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels |
| Q41732419 | Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study |
| Q34527367 | Gabapentin and (S)-pregabalin decrease intracellular D-serine concentrations in PC-12 cells |
| Q60670852 | Gabapentin and Pregabalin for the Treatment of Anxiety Disorders |
| Q39323350 | Gabapentin as a potential option for treatment of sciatica |
| Q34266645 | Gabapentin attenuates hyperexcitability in the freeze-lesion model of developmental cortical malformation |
| Q39504921 | Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study |
| Q30248950 | Gabapentin for post-operative pain management - a systematic review with meta-analyses and trial sequential analyses. |
| Q47309377 | Gabapentin for the treatment of alcohol use disorder. |
| Q33823366 | Gabapentin in procedure-specific postoperative pain management - preplanned subgroup analyses from a systematic review with meta-analyses and trial sequential analyses |
| Q36872261 | Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats |
| Q43970806 | Gabapentin reduces preoperative anxiety and pain catastrophizing in highly anxious patients prior to major surgery: a blinded randomized placebo-controlled trial |
| Q42584605 | Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia |
| Q37577544 | Gabapentin treatment for alcohol dependence: a randomized clinical trial |
| Q38684487 | Gabapentin: Abuse, Dependence, and Withdrawal |
| Q97540059 | Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis |
| Q59326711 | Hipoventilación central por gabapentina |
| Q38653220 | Inhibitory dysfunction in amyotrophic lateral sclerosis: future therapeutic opportunities |
| Q42292935 | Injury to skeletal muscle of mice following acute and sub-acute pregabalin exposure |
| Q35758344 | International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe |
| Q37851908 | Ion channel blockers and spinal cord injury |
| Q61811700 | Management of Hereditary Spastic Paraplegia: A Systematic Review of the Literature |
| Q31061153 | Management of focal-onset seizures: an update on drug treatment |
| Q24651951 | Modifications of antiepileptic drugs for improved tolerability and efficacy |
| Q28681145 | Molecular mechanisms of antiseizure drug activity at GABAA receptors |
| Q41960088 | NF-κB mediated regulation of adult hippocampal neurogenesis: relevance to mood disorders and antidepressant activity |
| Q26995739 | Neuropeptide modulation of central amygdala neuroplasticity is a key mediator of alcohol dependence. |
| Q47837913 | Neurotransmitter deficits from frontotemporal lobar degeneration |
| Q35046545 | New Horizons in the development of antiepileptic drugs: Innovative strategies |
| Q34418303 | New and emerging therapeutic agents for the treatment of fibromyalgia: an update |
| Q37709565 | New approaches for the treatment of sleep disorders |
| Q37106971 | New treatment options in the management of fibromyalgia: role of pregabalin |
| Q38222436 | Novel Pharmacologic Approaches to Treating Cannabis Use Disorder |
| Q33875227 | Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological Methods |
| Q38759454 | Optogenetic Approaches to Drug Discovery in Neuroscience and Beyond |
| Q33713626 | Oxycodone combinations for pain relief. |
| Q38016449 | P/Q-type calcium channel modulators |
| Q91829966 | Pain And The Use Of Gabapentinoids In German Nursing Home Residents - Results From An Analysis Based On Statutory Health Insurance Data |
| Q60306664 | Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: An open label clinical trial |
| Q38198088 | Pain in spinal cord injury |
| Q34714598 | Paradoxical worsening of seizure activity with pregabalin in an adult with isodicentric 15 (IDIC-15) syndrome involving duplications of the GABRB3, GABRA5 and GABRG3 genes |
| Q28247954 | Paroxysmal sympathetic hyperactivity after severe brain injury |
| Q58096508 | Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity |
| Q37165500 | Pharmacological management of neuropathic pain following spinal cord injury |
| Q38370071 | Pharmacological options for the management of refractory cancer pain-what is the evidence? |
| Q42353634 | Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease |
| Q37810291 | Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components |
| Q37141499 | Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients |
| Q47974257 | Possible involvement of ATP-sensitive potassium channels in the antidepressant-like effects of gabapentin in mouse forced swimming test |
| Q44066305 | Pregabalin abuse and dependence in Germany: results from a database query |
| Q24186173 | Pregabalin for decreasing pancreatic pain in chronic pancreatitis |
| Q24186310 | Pregabalin for decreasing pancreatic pain in chronic pancreatitis |
| Q37263402 | Pregabalin for neuropathic pain based on recent clinical trials |
| Q37803241 | Pregabalin for the treatment of postsurgical pain |
| Q28270317 | Pregabalin in the treatment of alcohol and benzodiazepines dependence |
| Q42923165 | Pregabalin-induced severe delayed ejaculation |
| Q48944583 | Pregabalin: a treatment option for dystonia? |
| Q48097333 | Preoperative pregabalin does not reduce propofol ED(50): a randomized controlled trial |
| Q40851518 | Psychotic and depressive symptoms after gabapentin treatment |
| Q39251785 | Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. |
| Q26825721 | Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity |
| Q48313483 | Remarkable Modulation of Self-Assembly in Short γ-Peptides by Neighboring Ions and Orthogonal H-Bonding. |
| Q38691963 | Rhabdomyolysis induced by antiepileptic drugs: characteristics, treatment and prognosis. |
| Q47300675 | Sedative effects of oral pregabalin premedication on intravenous sedation using propofol target-controlled infusion |
| Q36624486 | Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol |
| Q45074562 | Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy. |
| Q55367606 | Short-term incubation of gabapentin or pregabalin does not affect chemically induced injury in neuronal cell models in vitro. |
| Q36065879 | Small endogenous molecules as moiety to improve targeting of CNS drugs. |
| Q42318992 | Spatiotemporal correlation of spinal network dynamics underlying spasms in chronic spinalized mice. |
| Q45918529 | Stability of gabapentin 300-mg capsules repackaged in unit dose containers. |
| Q58100058 | State-of-the-art behavioral and pharmacological treatments for alcohol use disorder |
| Q42366816 | Stereochemical Control of Enzymatic Carbon-Carbon Bond-Forming Michael-Type Additions by "Substrate Engineering". |
| Q35624302 | Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers |
| Q34820741 | Summation model of pelvic pain in interstitial cystitis |
| Q48269990 | Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice |
| Q43953111 | Synthesis and stereochemical analysis of β-nitromethane substituted γ-amino acids and peptides |
| Q38686593 | The Role of Calcium Channels in Epilepsy |
| Q39274579 | The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial |
| Q36526507 | The central amygdala and alcohol: role of γ-aminobutyric acid, glutamate, and neuropeptides |
| Q33861512 | The effects of gabapentin pretreatment on brain injury induced by focal cerebral ischemia/reperfusion in the rat. |
| Q45068836 | The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. |
| Q34583067 | The prophylactic treatment of chronic daily headache |
| Q44902532 | The relationship between gabapentin and pregabalin and posttraumatic stress disorder in burned servicemembers |
| Q34440686 | The structural biology of voltage-gated calcium channel function and regulation |
| Q37313452 | Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. |
| Q47547579 | Treatment of Generalized Anxiety Disorder with Gabapentin |
| Q92459370 | Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments |
| Q37203259 | Use of second-generation antiepileptic drugs in the pediatric population |
| Q51744399 | Visual field defect during therapy with valproic-acid. |
| Q36525559 | Voltage-gated calcium channels and idiopathic generalized epilepsies. |
| Q36666506 | What is new in neuropathic pain? |
| Q89963752 | Zebrafish as a Model System for the Study of Severe CaV2.1 (α1A) Channelopathies |
Search more.